{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"137"}]}],"title":"<450 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"title":"450 msec to <480 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"480 msec to <500 msec"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}],"title":">=500 msec"}],"denoms":[{"counts":[{"groupId":"OG000","value":"155"}],"units":"Participants"}],"description":"QT interval corrected using Fridericia's formula (QTcF): QT interval (time corresponding to the beginning of depolarization to re-polarization of the ventricles) divided by cube root of RR interval. Maximum QTcF was categorized as less than (\\<) 450 milliseconds (msec), 450 msec to \\<480 msec, 480 msec to \\<500 msec, and more than or equal to (\\>=) 500 msec. A participant is reported only once under the maximum QTcF interval observed at any of the time-points. Only participants receiving crizotinib were to be analyzed for this outcome measure as per planned analysis.","groups":[{"description":"Crizotinib (PF-02341066) 250 mg (administered as two 100-mg tablets and one 50-mg tablet) orally twice daily continuously in 21-day cycles. Treatment was continued until disease progression, unacceptable toxicity or withdrawal of consent occurred.","id":"OG000","title":"Crizotinib"}],"paramType":"NUMBER","populationDescription":"ECG-evaluable population included all randomized participants who received at least 1 dose of study treatment, and had a baseline and at least 1 post-baseline ECG measurement.","reportingStatus":"POSTED","timeFrame":"Pre-dose on Day 1 of Cycle 1, 2 to 6 hours post-dose on Day 1 of Cycle 1, 2","title":"Number of Participants With Categorical Maximum QTcF for Crizotinib","type":"SECONDARY","unitOfMeasure":"participants"}